DaVita (NYSE:DVA) Price Target Cut to $215.00 by Analysts at Truist Financial

Key Points

• Truist Financial cut DaVita’s price target from $250 to $215 while maintaining a “hold” rating, implying approximately 19.4% upside from the reported $180.06 share price.
• Analyst sentiment is mixed: TD Cowen and Weiss Ratings upgraded the stock to “buy,” while UBS raised its target to $270; overall, DaVita has an average “hold” rating and a consensus price target of $221.75.
• DaVita exceeded quarterly expectations, reporting $4.02 in EPS versus $3.88 expected and $3.55 billion in revenue versus $3.50 billion expected. Revenue increased 5.2% year over year, and management issued fiscal 2026 EPS guidance of $14.10–$15.20.

DaVita (NYSE:DVA - Get Free Report) had its target price lowered by equities researchers at Truist Financial from $250.00 to $215.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a "hold" rating on the stock. Truist Financial's price target would indicate a potential upside of 19.40% from the stock's current price.

Other equities research analysts have also issued research reports about the stock. TD Cowen raised shares of DaVita from a "hold" rating to a "buy" rating and set a $220.00 price objective on the stock in a research note on Friday. Weiss Ratings upgraded shares of DaVita from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday. Raymond James Financial set a $220.00 price target on DaVita in a research report on Friday. UBS Group upped their price target on DaVita from $235.00 to $270.00 and gave the stock a "buy" rating in a research note on Friday, July 10th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a $265.00 price objective on shares of DaVita in a research note on Wednesday. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $221.75.

DaVita Stock Down 0.3%

Shares of DVA stock opened at $180.06 on Friday. The business's fifty day moving average is $218.65 and its 200 day moving average is $176.48. The stock has a market cap of $11.49 billion, a price-to-earnings ratio of 14.83, a PEG ratio of 0.63 and a beta of 0.88. DaVita has a twelve month low of $101.00 and a twelve month high of $247.49.

DaVita (NYSE:DVA - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, beating analysts' consensus estimates of $3.88 by $0.14. The firm had revenue of $3.55 billion for the quarter, compared to analysts' expectations of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The company's quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities research analysts expect that DaVita will post 14.7 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the sale, the insider owned 109,194 shares in the company, valued at $22,756,029.60. This represents a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 1.90% of the company's stock.

Hedge Funds Weigh In On DaVita

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Root Financial Partners LLC raised its stake in shares of DaVita by 128.0% in the first quarter. Root Financial Partners LLC now owns 187 shares of the company's stock worth $29,000 after purchasing an additional 105 shares during the last quarter. Caitlin John LLC purchased a new position in DaVita in the 4th quarter worth about $34,000. Sankala Group LLC bought a new position in DaVita during the 4th quarter valued at about $39,000. Canada Pension Plan Investment Board bought a new stake in shares of DaVita in the second quarter worth approximately $43,000. Finally, Kestra Advisory Services LLC purchased a new position in shares of DaVita during the fourth quarter valued at approximately $45,000. 90.12% of the stock is owned by institutional investors.

DaVita Company Profile

DaVita Inc NYSE: DVA is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source